Key result
Patients with advanced cancer displayed significantly higher resting cardiac output (5.5 vs 4.5 L/min) and stroke volume (78 vs 66 ml) compared to healthy controls.
Why the study?
How do non-invasive cardiac hemodynamic parameters differ between patients with advanced cancer, chronic heart failure, and healthy controls?
Cross-Sectional (n=98)
No
How do non-invasive cardiac hemodynamic parameters differ between patients with advanced cancer, chronic heart failure, and healthy controls?
Non-invasive hemodynamic assessment reveals that patients with advanced cancer have elevated stroke volume and cardiac output compared to controls, potentially indicating increased cardiovascular risk.
Elevated CO/SV in advanced cancer may signal CV vulnerability; hypothesis-generating and should not yet change practice.
INTRODUCTION: Relationships between cardiac pressure and volume have been suggested as markers of cardiac contractility; parameters include stroke work and the maximal rate of pressure rise during isovolumic contraction (dP/dtmax). Patients with cancer often display dyspnea and fatigue. These are also frequent symptoms in patients with chronic heart failure (HF). The reasons for similar symptoms in cancer patients are unknown. Using the novel Nexfin Finapres technique, we sought to assess measures of cardiac performance in patients with cancer and compare these values with those from control subjects and patients with chronic HF. MATERIAL AND METHODS: We prospectively studied 98 patients (control n = 18, chronic HF n = 37, advanced pancreatic or colorectal cancer n = 43) and assessed blood pressure (BP), stroke volume (SV), cardiac output (CO), and dP/dtmax at rest. RESULTS: All parameters of interest could be assessed using the Nexfin Finapres technique with SV and CO being significantly higher in patients with cancer than in controls (both p < 0.05). The SV was significantly higher in patients with chronic HF than in controls (p < 0.05). In patients with cancer, SV correlated with age (r = -0.45, p < 0.01) and body weight (r = +0.55, p = 0.0001). In chronic HF, SV declined with increasing age (r = -0.49, p < 0.01); in control subjects, SV increased with increasing body weight (r = +0.57, p = 0.01). CONCLUSIONS: Patients with cancer tended to display elevated BP, CO, SV, and dP/dtmax as compared to control subjects and patients with HF. These findings may reveal an elevated risk for cardiovascular diseases in this group.
No takes yet. Share an insight, caveat, or question.
Haehling et al. (2013) conducted a cross-sectional in Advanced cancer and chronic heart failure (n=98). Advanced cancer vs. Healthy controls was evaluated on Cardiac output at rest (L/min) (p=<0.05). Patients with advanced cancer displayed significantly higher resting cardiac output (5.5 vs 4.5 L/min) and stroke volume (78 vs 66 ml) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: